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Abstract
Introduction: The pathophysiology of spinal cord injury (SCI) has a classically bad prognosis. It has been demonstrated that
human umbilical cord blood stem cells (hUCBSCs) and Melissa officinalis (MO) are useful for the prevention of neurological
disease.
Methods: Thirty-six adult male rats were randomly divided into intact, sham, control (SCI), MO, hUCBSC, and
MO-hUCBSC groups. Intraperitoneal injection of MO (150mg/kg) was commenced 24 hr post-SCI and continued once a
day for 14 days. Intraspinal grafting of hUCBSCs was commenced immediately in the next day. The motor and sensory
functions of all animals were evaluated once a week after the commencement of SCI. Electromyography (EMG) was per-
formed in the last day in order to measure the recruitment index. Immunohistochemistry, reverse transcription-polymerase
chain reaction, and transmission electron microscopy evaluations were performed to determine the level of astrogliosis and
myelination.
Results: The results revealed that motor function (MO-hUCBSC: 15 0.3, SCI: 8.2 0.37, p< .001), sensory function (MO-
hUCBSC: 3.57 0.19, SCI: 6.38 0.23, p< .001), and EMG recruitment index (MO-hUCBSC: 3.71 0.18, SCI: 1.6 0.1,
p< .001) were significantly improved in the MO-hUCBSC group compared with SCI group. Mean cavity area (MO-hUCBSC:
0.03 0.03, SCI: 0.07 0.004, p< .001) was reduced and loss of lower motor neurons (MO-hUCBSC: 7.6 0.43, SCI:
3 0.12, p< .001) and astrogliosis density (MO-hUCBSC: 3.1 0.15, SCI: 6.25 1.42, p< 0.001) in the ventral horn of spinal
cord were prevented in MO-hUCBSC group compared with SCI group.
Conclusion: The results revealed that the combination of MO and hUCBSCs in comparison with the control group has
neuroprotective effects in SCI.
Keywords
astrogliosis, human umbilical cord blood, Melissa officinalis, myelination, spinal cord injury
Received March 13, 2016; Received revised May 17, 2016; Accepted for publication July 6, 2016
Introduction
The spinal cord injury (SCI) is very common and has
poor prognosis (Webb et al., 2010). SCI could cause
severe damage to motor, sensory, and autonomic nervous
system and their functions which may lead to severe dis-
abilities (Coutts and Keirstead, 2008). The pathophysi-
ology of SCI after the primary trauma has a vital role
in the initial structural disruption. In addition, the sec-
ondary process includes the cascades of cellular and
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biological disruptions which can lead to long-term spinal
deﬁcits (Dasari et al., 2014). Increased oxidative stress
(Fatima et al., 2015), redox transcription factors activity
as well as elevated expression of inﬂammatory mediators
play important roles (Popovich and Jones, 2003) in the
promotion of the secondary process after the initial
injury. SCI results in structural deformation such as
degeneration of axons, disruption of neural tissue,
neural and glial cell death, and demyelination around
the lesion site. Axonal regeneration is inhibited by
myelin-associated inhibitors in the central nervous
system (CNS; Geoﬀroy and Zheng, 2014) and formation
of astrogliosis (Deng et al., 2011). The extent of intrinsic
cell renewal alone (Li and Lepski, 2013), even after appli-
cation of mitogenic agents such as variety of growth fac-
tors, is not suﬃcient enough for substantial recovery
following SCI (Chhabra and Sarda, 2015). So, thera-
peutic approaches such as exogenous cell transplantation
should be considered.
Human umbilical cord blood stem cells (hUCBSCs)
hold great promise for therapeutic repair after SCI
(Dasari et al., 2007). The human umbilical cord blood
by diﬀerentiating into various neural cells can enhance
motor and sensory function improvement in the animal
models of SCI (Kuh et al., 2005).
Transplantation of human umbilical cord blood
mononuclear cells into the injured site of spinal cord
did not aﬀect the lesion extension. The survival time of
transplanted cells in the injured area was 6 weeks after
treatment. The transplanted group indicated better func-
tional recovery than the untreated ones (Rodrigues et al.,
2012). There is suﬃcient evidence which prove that
stem cell therapy could be eﬀective in spinal cord injuries
but a strategy to potentiate this stem cell transplantation
results is required (Niapour et al., 2012; Chhabra and
Sarda, 2015).
As there have been strong interests in ﬁnding traditional
agents that may help in the prevention of inﬂammation
and disruption of neural tissues in CNS, a well-known
herbal drug which has exhibited antioxidant and neuro-
protective eﬀects is Melissa oﬃcinalis (MO). MO is com-
monly known as lemon balm (family: Lamiaceae); it is one
of the oldest and still the most common medicinal plants
(Kamdem et al., 2013). It has been reported that the most
commonly known therapeutic properties of MO extract
were sedative, antispasmodic, carminative, antibacterial,
antiviral, antiinFammatory, antioxidant, as well as neuro-
protective (Kamdem et al., 2013). It was previously shown
that the eﬀective dose of MO was 150mg/kg in SCI con-
tusive model, and it was also shown that MO extract was
eﬀective in improving motor, sensory, and cellular func-
tion after injury (Hosseini et al., 2015). Therefore, the aim
of this study is to assess the eﬀectiveness of the MO extract
in combination with hUCBSC transplantation after
contusive SCI in Wistar rats. It was hypothesized that
the combination of MO and hUCBSCs may play a role
in preventing harmful eﬀects and neural damage triggered
by SCI.
Materials and Methods
Animals
After obtaining the approval of the Institutional Review
Board of our university, all experiments were carried out
in accordance with the Guidelines for the Animal Care
and use ethics committee of the Baqiyatallah University
of medical sciences. Thirty-six adult male Wistar rats
weighing from 190 to 220 g were maintained under stand-
ard laboratory conditions. Animals were housed in an
environment of 21 2C with a relative humidity of 50
to 10% and a 12-hr light–dark cycle. Food and water
were always available.
Surgical Procedure for SCI
To make SCI, the animals were anesthetized with 80mg/
kg ketamine hydrochloride and 10mg/kg xylazine hydro-
chloride (Alfasan Company, Netherlands) intraperitone-
ally. Weight-drop contusion method was conducted to
induce SCI in rats. The skin and subcutaneous tissues
in the thoracolumbar T12-L1 region were incised. After
penetration of paravertebral muscle fascia, muscles were
peeled laterally using blunt dissection forceps. The spinal
cord segment at T12-L1 level was exposed by total lamin-
ectomy. The animals were subjected to an impact of 10 g
weight (stainless steel rod, 3mm diameter tip) dropped
vertically in the center of the exposed spinal cord from
the height of 25mm (severe; Agrawal et al., 2010). In the
sham group, all mentioned procedures were carried out,
except the spinal cord contusion. The ﬁnal procedure was
incision suturing (Byrnes et al., 2010).
Core body temperature of animals was maintained at
36.5 to 37.5C during and after the study procedures. The
rats were treated with gentamicin (40mg/kg, intramuscu-
lar injection; Caspian Tamin Company, Iran) twice a day
for the ﬁrst 3 days as prophylaxis against urinary tract
infection. The urinary bladders were pressed three times a
day by the time that bladder function returned to normal.
The rats were also injected subcutaneously with 25ml/kg
lactated Ringer’s solution (Caspian Tamin Company,
Iran) for 2 days after SCI as once a day (Edalat et al.,
2013).
Plant Collection and Extractions
The plant was taken from the commercial source. The
dried leaves powder of MO was macerated at room tem-
perature in 70% ethanol (1 g/10ml) and extracted for a
week. On the seventh day, the ethanolic extract was
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reﬁned and the extract was evaporated under reduced
pressure to remove the ethanol. The dry extract was sus-
pended in the normal saline and thus alcoholic extract of
MO was prepared. We have previously shown that most
eﬀective dose of MO in the animal model of SCI is
150mg/kg. So, in this study, we administered 150mg/kg
of MO (Pereira et al., 2009; Hosseini et al., 2015).
Animal Groups and Drugs Administration
Rats were randomly divided into six groups as follows:
Group †: intact group (n¼ 5), Group ††: sham rats were
subjected to laminectomy without SCI (n¼ 5), Group †††:
rats were subjected to laminectomy and SCI (n¼ 5),
Group †V: rats were subjected to laminectomy, SCI,
and treated with 150mg/kg MO (SCI-MO; n¼ 7),
Group V: rats were subjected to laminectomy, SCI, and
treated with hUCBSCs (SCI-hUCBSC; (n¼ 7), Group
V†: rats were subjected to laminectomy, SCI, and treated
with combination of 150mg/kg MO and hUCBSCs (SCI-
MO-hUCBSC; n¼ 7). hUCBSCs were transplanted
intraspinally 24 hr after injury. MO was daily injected
intraperitoneally into treatment rat groups starting 1
day after injury for 14 days.
Culture of hUCBSCs
Human umbilical cord blood was collected from healthy
women aged between 20 and 40 years with informed consent
and according to the protocol approved by Institutional
Review Board of Baqiyatallah University of Medical
Sciences. Thereafter, human umbilical cord blood was trans-
ferred into Falcon tube containing phosphate buﬀered saline
(PBS) without Ca2þ or Mg2þ supplemented with 2.5mg/ml
fungizone, 100mg/ml streptomycin, 100U/ml penicillin, and
0.5Mm ethylenediaminetetraacetic acid (All from Merck,
Germany). Mononuclear cells were separated utilizing
Ficoll-Hypaque (Sigma, St. Louis, MO) density gradient
centrifugation and washed out in PBS. Thereafter, the cell
pellet in the tube was suspended in Dulbecco’s modiﬁed
Eagle medium and Ham’s F-12 (DMEM-F12) medium sup-
plemented with 10% fetal bovine serum (FBS; All from
Sigma) and cultured in tissue culture plates. The cells were
kept in the 37C incubator with 5% CO2 and saturated
humidity. After removing nonadherent cells in the second
day of incubation, the culture of adherent cells continued
until 70% conﬂuency (Dasari et al., 2007; Faramarzi et al.,
2016). At Passage 4, the cells were checked for the properties
of mesenchymal stem cells using ﬁbronectin (þ), CD44 (þ),
and CD45 () (Santa Cruz Biotechnology, Santa Cruz, CA)
immunostaining. The dissociated mesenchymal cells were
further dispersed in 10% FBS-DMEM and counted under
a microscope with the aid of a hemocytometer. The mesen-
chymal cells were then utilized directly for cultures or stored
in liquid nitrogen for later use.
5-Bromo-20-Deoxyuridine Labeling
To enable the visualization of hUCBSCs after their trans-
plantation into the spinal cord, their nuclei were labeled
with 5-bromo-20-deoxyuridine (BrdU). BrdU (Merck,
Germany) at the ﬁnal concentration of 10mg/ml was
added to the culture of the hUCBSCs 24 hr before trans-
plantation. The excess tracer was washed out with PBS
and cells were suspended in fresh culture medium to
obtain approximately 300,000 cells in 10 ml.
Intra-Spinal Grafting of hUCBSCs
Animals were reanesthetized as described earlier, and the
laminectomy site was re-exposed. Sham group animals
were injected 24hr after laminectomy with 9ml of normal
saline by utilizing a10ml Hamilton syringe (Sigma). The
hUCBSCs-treated group was injected 24hr after injury.
The mononuclear cell layer of hUCBSC (3 105 ells/mL)
in 9ml of normal saline at a rate of 0.25ml/min was trans-
planted into the three sites of lesion area (epicenter, distal,
and proximal) at a depth of 1.2mm. The hUCBSCs were
previously labeled with BrdU so as to facilitate the identi-
ﬁcation of the cells within the subsequent histological spe-
cimens. Cyclosporine A (10mg/kg; (Sigma) was
administered as an immunosuppressant for 7 days after
transplantation of hUCBSCs (Dasari et al., 2007).
Neurological Examination
For assessment of neurological function, the Basso–
Beattie–Bresnahan (BBB) scale was used for open ﬁeld
motor testing in all rat groups. The BBB scale is a 21-
point scale ranging from 0 to 21 (Barros Filho and
Molina, 2008), rating locomotion on aspects of hind
limb function such as weight support, stepping ability,
coordination, and toe clearance (Byrnes et al., 2010).
All functional scores were obtained on Days 1, 7, 14,
21, 28, 35, 42, 49, and 56 by two individuals who were
blinded to treatment. The ﬁnal score of each animal was
the mean value of both examiners (Hosseini et al., 2015).
Behavioral test for evaluation of sense of pain was per-
formed by means of hot water test for the hind limbs after
SCI (scores were obtained on Days 1, 7, 14, 21, 28, 35, 42,
49, and 56). The response to heat stimulation was measured
by the latency of hind limb paw withdrawal of hot water at
50C. Both paws of rats were kept in a hot water container,
respectively. For each rat, six trials were obtained (three
trials for each paw), and mean of this trials were recorded,
and nonresponders were removed from the hot water con-
tainer after 60 s (Kim et al., 2013; Hosseini et al., 2015).
Electrophysiological Evaluations
Spontaneous rest activity was recorded from hind limb
ﬂexor muscle bilaterally. Electromyography (EMG)
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recording was done by 23 gauge needles for 10 s one day
prior to sacriﬁce of animals. The EMG signal was ampli-
ﬁed (Grass, Astro-Med, West Warwick, RI), digitized
(5 kHz, Digi-data 1322A; Axon instruments, Foster
City, CA), and ﬁltered (30–300Hz; Fouad et al., 2013).
After recording, the recruitment index of motor units was
acquired via compression of 10 s of recording to 1 s by
EMG software. The recruitment index was scored on an
ordinal scale (0 to þþþþ) (Sta˚lberg et al., 1998; Hosseini
et al., 2015).
Histology and Immunohistochemistry
On Day 57, all rats were anesthetized (100mg/kg sodium
pentobarbital, I.P.). Thereafter intracardially perfused
with 0.9% saline followed by 10% buﬀered formalin. A
spinal cord segment at the level of T12-L1 was dissected,
postﬁxed in 10% buﬀered formalin overnight, cryopro-
tected in 30% sucrose for 48 hr and serially transverse
sectioned using a cryostat (B1155800 Sakura) at 10 mm
thickness. All sections were processed for hematoxylin
and eosin staining and assessed under light microscopy
(Byrnes et al., 2010). Standard immunohistochemistry for
the glial scar (glial ﬁbrillary acidic protein) and myelin-
ation (myelin basic protein [MBP]) was performed for all
of the sections. For immunohistochemistry, sections from
formalin-ﬁxed, paraﬃn-embedded spinal cord tissues
were dewaxed, rehydrated, and retrieval of antigens was
performed. After incubation with 3% H2O2 in methanol,
and then normal nonimmune goat serum, the sections were
incubated with rabbit antiactive glial ﬁbrillary acidic protein
(GFAP) polyclonal antibody and mouse monoclonal MBP
primary antibody (Santa Cruz Biotechnology), at a dilution
of 1:200 at 4C for overnight, followed by biotinylated goat
anti-rabbit IgG for 20min at room temperature, and sub-
sequently incubated with streptavidin–peroxidase (All from
Santa Cruz Biotechnology). PBS replaced primary antibody
as the negative control. 3,30-Diaminobenzidine chromogen
was applied for visualization of peroxidase activity. Finally,
the sections were counterstained with hematoxylin (Fleming
et al., 2006; Hosseini et al., 2015).
Histomorphometric Analysis
The lesion area including the cavity and surrounding
damaged tissue in area of 3562,500 mm2, was then mea-
sured by using an image analyzing software (Motic 2.1,
Italy, Cagli); in addition, the number of lower motor
neurons in area of 5,700 mm2, the number of positive
GFAP astrocyte perikaryon in ventral horn, and area
of 35,625 mm2 were measured. Only those cells that
showed clearly discernible nucleus were counted.
Densities of myelin in dorsal white matter and astroglio-
sis in the ventral horn of spinal cord were evaluated by
using of histolab software (Iran, 1392). Five sections from
each case were evaluated, and mean values were obtained
for each animal. Cell counting and densitometry analyzes
were carried out by two observers who were blind to the
speciﬁc experimental conditions of the analyzed tissues
on images acquired at 40, 400, and 1000
magniﬁcations(Bharne et al., 2013).
Transmission Electron Microscopic Studies
For electron microscopy, spinal cords from ﬁve rats from
each treatment group were processed into small 3mm3
blocks that surrounded the injury epicenter and ﬁxed
for 1 hr in a mixture of glutaraldehyde (1.5%) and par-
aformaldehyde (3%), followed by washing three times in
0.1M sodium cacodylate and 3mM CaCl2. Samples were
then postﬁxed in potassium ferrocyanide (0.8%) and
osmium tetroxide (1%) for 1 hr followed by 3 washes
in 0.1M sodium cacodylate and 3mM CaCl2 (All from
Sigma). Ensuing a brief dH2O rinse, samples were
embedded in Eponate 12 (Pelco, Clovis, CA) and cured
at 60C for 2 days. Spinal cord sections (80 nm in thick-
ness) corresponding to the site of the lesion were cut on a
Reichert Ultracut E with a Diatome diamond knife, col-
lected on formvar-coated 1 2mm2 copper grids, and
stained with uranyl acetate followed by lead citrate.
Sections were examined on a Hitachi 7600 transmission
electron microscope operating at 80 kV. The myelin index
(MI) was measured by means of the ratio of axon diam-
eter to axon diameter plus its myelin sheath (Wrathall
et al., 1998; Pang et al., 2012).
RNA Extraction and Reverse Transcription-
Polymerase Chain Reaction
T12-L1 segments of spinal cord from various groups were
homogenized and total RNAs were isolated using
RNeasy Mini Kit (Qiagen, Valencia, CA) according to
the manufacturer’s protocol. Approximately 1 mg of
total RNA from each sample was reverse transcribed
into cDNA according to the manufacturer’s instructions
using the iScripTM cDNA Synthesis Kit (Bio-Rad
Laboratories, Hercules, CA). Glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) was applied as an inter-
nal control. We used the following sequences for the
forward and reverse primers:
For MBP: Forward primer—5CTCTGGCAAGGAC
TCACACA3 and reverse primer—5GTCTCTTCCTCCC
CAGCTA3; For GAPDH: Forward primer—5CCACC
CATGGCAAATTCC3, and reverse primer—5CAGGA
GGCATTGCTGATGAT3.
The housekeeping gene GAPDH was used for normal-
ization of MBP mRNA expression. Samples were sub-
jected to 25 to 35 cycles at 95C for 30 s, 60C for 30 s,
and 72C for 1min on GeneAmp PCR System 9700
(Perkin Elmer, Boston, MA) in 25 ml reaction volumes.
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After ampliﬁcation, reverse transcription-polymerase
chain reaction products were separated on a 1% agarose
gel containing 0.5mg/ml ethidium bromide. The ampli-
ﬁed cDNA fragments were visualized under ultraviolet
light (Dasari et al., 2007).
Statistical Analyses
Data obtained from motor and sensory functions at each
time point as well as electromyographic activity between
diﬀerent groups were analyzed utilizing two-way analysis
of variance (ANOVA). The histomorphometric, immu-
nostaining data, densitometry, and electron microscopic
data were analyzed using one-way ANOVA. In both
tests, ANOVA was followed by post hoc Bonferroni’s
multiple comparison tests. Data were presented as the
meanSEM and a signiﬁcance level of .05 was predeter-
mined for all statistical analysis.
Results
In all experiments, there were no signiﬁcant diﬀerences
between sham and intact groups, but signiﬁcant diﬀer-
ences were seen between intact and SCI groups
(p< .001). In fact, the main index for SCI model induc-
tion was this signiﬁcance.
Presence of fibronectin and CD44 on hUCBSCs
and Tracking of Transplanted Cells in Spinal Cord
Lesion Area
Immunocytochemistry examination detected the local-
ization of ﬁbronectin and CD44 on hUCBSCs. The per-
centage of positivity was 89.67 and 94.78%, respectively.
hUCBSCs were negative for the marker CD45 (Figure 1).
Furthermore, immunoﬂuorescence studies revealed the
presence of transplanted cells in lesion area of the
spinal cord (Figure 2).
Neurological Function Results
Combination of MO extract and hUCBSCs transplantation
increased the motor and sensory functions after SCI. SCI
resulted in immediate paraplegia (loss of hind limb move-
ment); hence the SCI group demonstrated significant
changes in locomotion scores in comparison with intact
group. hUCBSCs significantly enhanced locomotors func-
tion in rats when compared with SCI group. Furthermore,
when intraperitoneal MO (150 mg/kg) was added a day after
the injury, it significantly improved locomotors function in
rats when compared with SCI group. The application of two-
way ANOVA showed significant interaction between vari-
ables such as hUCBSCs therapy, MO treatment, and time,
Figure 1. Characterization of hUCBSCs. (a) Cells stain positive for fibronectin (brown). (b) Cells stain positive (brown) for CD44. (c)
Cells do not stain for CD45. (d) Cells labeled with BrdU. Note. hUCBSCs¼ human umbilical cord blood stem cells; BrdU¼ Br5-bromo-20-
deoxyuridine.
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Figure 2. Transplanted hUCBS cells in the injured spinal cord, with anti-BrdU antibody as a primary antibody followed by the second-
ary antibody conjugated with FITC. The figure represents a qualitative feature of the immunostained cells (a). (b) Shows phase contrast
of (a) picture. Note. hUCBS¼ human umbilical cord blood stem; BrdU¼Br5-bromo-20-deoxyuridine; FITC¼ fluorescein isothiocyanate.
Figure 3. Effect of hUCBSC-MO treatment on motor function after SCI. Intraperitoneal injection of MO (150mg/kg) was started 1 day
after injury and continued once a day for 14 days after injury. Intraspinal grafting of hUCBSCs was started 24 hr after injury. Data are
represented as mean of BBB score SEM, (n¼ 5–7) and analyzed by two-way ANOVA followed by post hoc Bonferroni’s multiple
comparison test. ***p< .001 shows significant different between SCI versus intact. , and  show significant difference between SCI-
MO and SCI. , , and  show significant difference between SCI-hUCBSC and SCI. ##, and ### show significant difference
between SCI-MO-hUCBSC and SCI (p< .05, p< .01, and p< .001, respectively). Note. hUCBSCs¼ human umbilical cord blood stem cells;
MO¼Melissa officinalis; SCI¼ spinal cord injury; BBB¼Basso–Beattie–Bresnahan; ANOVA¼ analysis of variance.
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Figure 4. Effect of hUCBSC-MO treatment on sensory function after SCI. Intraperitoneal injection of MO (150mg/kg) was started 1 day
after injury and continued once a day for 14 days after injury. Intraspinal grafting of hUCBSCs was started 24 hr after injury. Data are
represented as mean of latency time SEM, (n¼ 5–7) and analyzed by two-way ANOVA followed by post hoc Bonferroni’s multiple
comparison test. ***p< .001 significant difference between SCI versus intact. , and  show significant difference between SCI-MO
and SCI. , and  show significant difference between SCI-hUCBSC and SCI. #, ##, and ### show significant difference between
SCI-MO-hUCBSC and SCI (p< .05, p< .01, and p< .001, respectively). Note. hUCBSCs¼ human umbilical cord blood stem cells;
MO¼Melissa officinalis; ANOVA¼ analysis of variance; SCI¼ spinal cord injury.
Figure 5. Effect of hUCBSC-MO on electromyographic activity after SCI. Intraperitoneal injection of MO (150mg/kg) was started a day
after injury and continued once a day for 14 days after injury. Intraspinal grafting of hUCBSCs was started 24 hr after injury. Data are
represented as mean of recruitment index SEM, (n¼ 5–7) and analyzed by two-way ANOVA followed by post-hoc Bonferroni’s multiple
comparison test. ***p< .001 shows significant difference between SCI versus intact. ##p< .01 and ###p< .001 versus spinal cord injury.
Note. hUCBSCs¼ human umbilical cord blood stem cells; MO¼Melissa officinalis; SCI¼ spinal cord injury; SEM¼ standard error of the
mean; ANOVA¼ analysis of variance.
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F(40, 270)¼ 29.37, p< .001. Application of post hoc
Bonferroni’s multiple comparison tests showed significant
improvement in motor function following 150 mg/kg MO
treatment on Day 35, 42 (p< .01), 49, and 56 (p< .001)
and hUCBSCs therapy on Day 14, 21 (p< .05), 28
(p< .01), 35, 42, 49, and 56 (p< .001) in comparison with
SCI group. Furthermore, the combination of MO and
hUCBSCs significantly enhanced motor function on Day
14, 28 (p< .01), 21, 35, 42, 49, and 56 (p< .001) in com-
parison with SCI group. There were no significant dierences
between SCI-MO, SCI-hUCBSC, and SCI-MO-hUCBSC
groups (Figure 3).
Statistical evaluations showed that the mean latency
time of response to the painful stimulus decreased signiﬁ-
cantly in SCI-hUCBSC group when compared with SCI
group. When intraperitoneal MO treatment (150mg/kg)
was added a day after the injury, it signiﬁcantly enhanced
sensory recovery in rats when compared with SCI group.
The application of two-way ANOVA showed signiﬁcant
interaction between variables including hUCBSCs, MO
treatment (150mg/kg), and time, F(40, 270)¼ 12.39,
p< .001. Application of post hoc Bonferroni’s multiple
comparison tests showed signiﬁcant improvement in sen-
sory function following 150mg/kg MO treatment on Day
28 (p< .01), 35, 42, 49, and 56 (p< .001) and hUCBSCs
therapy on Day 28 (p< .01), 35, 42, 49, and 56 (p< .001)
in comparison with SCI group. Moreover, combination
of MO and hUCBSCs signiﬁcantly improved motor func-
tion on Day 14 (p< .05), 21 (p< .001), 28, 35, 42, 49, and
56 (p< .001) in comparison with SCI group. There were
no signiﬁcant diﬀerences between SCI-MO, SCI-
hUCBSC, and SCI-MO-hUCBSC groups (Figure 4).
Figure 6. Effect of hUCBSC-MO treatment on cavity formation
after SCI. Intraperitoneal injection of MO (150mg/kg) was started
one day after injury and continued once a day for 14 days after
injury. Intraspinal grafting of hUCBSCs was started 24 hr after
injury. Data are represented as mean of the cavity area SEM
(n¼ 5–7) and analyzed by one-way ANOVA followed by post hoc
Bonferroni’s multiple comparison test. ***p< .001 shows significant
difference between SCI versus intact. ##p< .01, and ###p< .001
versus spinal cord injury.  shows significant difference between
SCI-MO-hUCBSC and SCI-hUCBSC (p< .05). $ shows significant
difference between SCI-MO-hUCBSC and SCI-MO (p< .05,
p< .01, and p< .001, respectively). Note. hUCBSCs¼ human
umbilical cord blood stem cells; MO¼Melissa officinalis;
SCI¼ spinal cord injury; SEM¼ standard error of the mean;
ANOVA¼ analysis of variance.
Figure 7. Effect of hUCBSC-MO treatment on cell loss in ventral
horn of spinal cord after injury. Intraperitoneal injection of MO
(150mg/kg) was started one day after injury and continued once a
day for 14 days after injury. Intraspinal grafting of hUCBSCs was
started 24 hr after injury. Data are represented as mean number of
ventral horn motor neurons SEM (n¼ 5–7) and analyzed by one-
way ANOVA followed by post hoc Bonferroni’s multiple compari-
son test. ***p< .001 shows significant difference between SCI
versus intact. #p< .05 and ###p< .001 versus spinal cord injury. 
show significant difference between SCI-MO-hUCBSC and SCI-
hUCBSC (p< .05). $$$ shows significant difference between SCI-
MO-hUCBSC and SCI-MO (p< .05, p< .01, and p< .001,
respectively). Note. hUCBSCs¼ human umbilical cord blood stem
cells; MO¼Melissa officinalis; SCI¼ spinal cord injury;
SEM¼ standard error of the mean; ANOVA¼ analysis of variance.
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Electrophysiological Results
Combination of MO extract and hUCBSCs transplantation
increased the recruitment pattern of hind limbs after SCI.
Although after the application of two-way ANOVA, there
was no significant dierence between the right and left hind
limb. The statistical analysis indicated that the means of
recruitment index were significantly increased for left and
right hind limbs in SCI-MO, SCI-hUCBSC, and SCI-MO-
hUCBSC groups when compared with SCI group, F(5,
60)¼ 0.01, p< .001. Application of post-hoc Bonferroni’s
multiple comparisons test as well as Bartlett’s test for
equal variances showed significant improvement in electro-
physiological activity of left and right hind limbs following
150 mg/kg of MO extract administration (p< .01), hUCBSC
therapy, and hUCBSC-MO treatment (p< 0.001) in com-
parison with SCI group. There were no significant dierences
between SCI-MO, SCI-hUCBSC, and SCI-MO-hUCBSC
groups (Figure 5).
Histological Results
Efficacy of MO-hUCBSCs treatment in reduction of cavity forma-
tion after SCI. In the intact group, spinal cord segments were
not damaged in both white and gray matter. Application of
one-way ANOVA demonstrated that the mean cavity size in
terms of mm2 was significantly reduced in treatment groups,
F(5, 30)¼ 27.95, p< .001. Moreover, post hoc Bonferroni’s
multiple comparison test illustrated the significant reduction
in the mean cavity area in SCI-MO, SCI-hUCBSC (p< .01),
and SCI-MO-hUCBSC (p< .001) groups when compared
with SCI group. Furthermore, application of one-way
ANOVA showed that mean cavity area in SCI-MO-
hUCBSC group was significantly reduced in comparison
with SCI-MO and SCI-hUCBSC groups (p< .05; Figure 6).
Combination of MO extract and hUCBSCs transplantation
decreased the lesioning of lower motor neurons in ventral horn
of spinal cord after its injury. Statistical evaluations showed
the significant dierences between SCI-MO, SCI-hUCBSC,
and SCI-MO-hUCBSC groups when compared with SCI
group based on the number of ventral horn lower motor
neurons, F(5, 30)¼ 30.86, p< .001. Application of post
hoc Bonferroni’s multiple comparisons test as well as
Bartlett’s test for equal variances revealed significant
increase in the number of ventral horn motor neurons in
SCI-MO (p< .05), SCI-hUCBSC, and SCI-MO-hUCBSC
Figure 8. Transverse section of spinal cord showing the lower motor neurons in ventral horn of spinal cord at the level of T12-L1 of all
groups which were evaluated in this study on Day 56. H&E staining showing shrinkage and reduction in ventral horn motor neurons in SCI
group in comparison with SCI-MO, SCI-hUCBSC, and SCI-hUCBSC-MO groups. Black arrows illustrate the ventral horn motor neurons
(400). a¼ SCI, b¼ SCI-hUCBSC, c¼ SCI-MO, d¼ SCI-MO-hUCBSC. Note. H&E¼ hematoxylin and eosin; hUCBSC¼ human umbilical
cord blood stem cell; MO¼Melissa officinalis; SCI¼ spinal cord injury.
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(p< .001) treatment groups when compared with SCI group.
Moreover, application of one-way ANOVA showed signifi-
cant dierence in SCI-MO-hUCBSC group when compared
with SCI-MO (p< .001) and SCI-hUCBSC (p< .05) groups
(Figures 7 and 8).
Immunohistochemistry and TEM Results
Effects of MO extract administration along with hUCBSCs trans-
plantation on GFAP expression after SCI. Statistical evaluations
revealed that the number of GFAPþ astrocytes was signifi-
cantly increased in SCI group. However, this activation was
significantly attenuated in the treatment groups, F(5,
30)¼ 45.49, p< .001. Application of post hoc Bonferroni’s
multiple comparisons test as well as Bartlett’s test for equal
variances showed a significant reduction in the GFAP
expression in SCI-MO, SCI-hUCBSC (p< .01), and SCI-
MO-hUCBSC (p< .001) treatment groups when compared
with SCI group. Statistically significant dierence was found
in GFAP expression between SCI-MO-hUCBSC group in
comparison with SCI-MO (p< .01) and SCI-hUCBSC
(p< .05) groups (Figures 9 and 10).
Data obtained revealed that the density of astrogliosis
in the ventral horn of spinal cord was signiﬁcantly
reduced in treatment groups in comparison with SCI
group, F(5, 30)¼ 17.66, p< .001. Moreover, post hoc
Bonferroni’s multiple comparison test showed that the
density of gliosis was signiﬁcantly reduced in SCI-
hUCBSC (p< .01) and SCI-MO-hUCBSC (p< .001)
groups when compared with SCI group. Statistical evalu-
ations showed signiﬁcant diﬀerences between SCI-MO-
hUCBSC, SCI-MO (p< .001), and SCI-hUCBSC
(p< .05) groups (Figure 11).
Effects of MO extract administration along with hUCBSCs trans-
plantation on myelination after SCI. Application of one-way
ANOVA demonstrated that density of myelin in the dorsal
white matter of spinal cord was significantly increased in
treatment groups when compared with SCI group, F(5,
30)¼ 62.11, p< .001. Furthermore, post hoc Bonferroni’s
multiple comparison test revealed that the density of
myelin was significantly increased in SCI-MO (p< .05),
SCI-hUCBSC, and SCI-MO-hUCBSC (p< .001) groups
compared with SCI group. Furthermore, statistical evalu-
ations showed significant dierences between SCI-MO-
hUCBSC, SCI-MO (p< .001), and SCI-hUCBSC (p< .05)
groups (Figures 12 and 13).
Conversely, evaluation of electron microscopic pic-
tures from all groups by application of one-way
ANOVA revealed that MI was reduced in treatment
groups, F(5, 6)¼ 102.1, p< .001. Moreover, post hoc
Bonferroni’s multiple comparison test showed that MI
was signiﬁcantly reduced in SCI-MO, SCI-hUCBSC
(p< .01), and SCI-MO-hUCBSC (p< .001) groups than
in SCI group. Statistical evaluations showed signiﬁcant
diﬀerences between SCI-MO-hUCBSC, SCI-MO, and
SCI-hUCBSC (p< .05) groups (Figures 13 and 14).
RT-PCR Results
Combination of MO extract and hUCBSCs transplantation
enhanced expression of MBP after SCI. For further confirm-
ation of myelination process and the synthesis of MBP by
MO-hUCBSC treatment after SCI, RT-PCR analysis was
used. There was a change in the mRNA levels after SCI
was determined utilizing standardized RT-PCR analysis.
Qualitative analysis of RT-PCR findings in all groups
revealed considerable upregulation of mRNA gene of MBP
in SCI-MO-hUCBSC treated group when compared with
SCI group. Application of one-way ANOVA revealed that
the density of RT-PCR bands was increased in treatment
Figure 9. Effect of hUCBSC-MO treatment on astrogliosis for-
mation in ventral horn of spinal cord after injury. Intraperitoneal
injection of MO (150mg/kg) was started one day after injury and
continued once a day for 14 days after injury. Intraspinal grafting of
hUCBSCs was started 24 hr after injury. Data are represented as
mean of GFAP-positive astrocytes SEM (n¼ 5–7) and analyzed by
one-way ANOVA followed by post hoc Bonferroni’s multiple
comparison test. ***p< .001 shows significant difference between
SCI versus intact. ##p< .01, and ###p< .001 versus spinal cord
injury.  shows significant difference between SCI-MO-hUCBSC
and SCI-hUCBSC (p< .05). $$ shows significant difference between
SCI-MO-hUCBSC and SCI-MO (p< .05, p< .01, and p< .001,
respectively). Note. hUCBSCs¼ human umbilical cord blood stem
cells; GFAP¼ glial fibrillary acidic protein; MO¼Melissa officinalis;
SCI¼ spinal cord injury; SEM¼ standard error of the mean;
ANOVA¼ analysis of variance.
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groups, F(5, 6)¼ 1077, p< .001. Moreover, post hoc
Bonferroni’s multiple comparison test revealed that the
density of RT-PCR bands was significantly increased in
SCI-MO (p< .01), SCI-hUCBSC. and SCI-MO-hUCBSC
(p< .001) groups than in SCI group. Application of one-
way ANOVA showed a significant dierence between SCI-
MO-hUCBSC, SCI-MO, and SCI-hUCBSC groups (p< .05;
Figures 15 and 16).
Discussion
Although some research work have indicated that stem
cell transplantation for treatment of SCI is unsuccessful
(Ru˚zˇicˇka et al., 2013), many investigations have demon-
strated that stem cells are eﬀective in SCI (Veeravalli
et al., 2009; Caron et al., 2016; Satti et al., 2016). As a
result, there has been controversy about this issue.
Figure 10. Transverse section of spinal cord showing the ventral horn gray matter of spinal cord at the level of T12-L1 of all groups which
were evaluated in this study on Day 56. Black arrows illustrate the GFAP astrocytes. Reduced GFAP astrocytes are evident. a¼ Intact,
b¼ SCI, c¼ SCI-MO, d¼ SCI-hUCBSC, e¼ SCI-MO-hUCBSC. Bar¼ 50mm. (ECLIPSE 5Oi microscope). Note. GFAP¼ glial fibrillary acidic
protein; hUCBSC¼ human umbilical cord blood stem cell; MO¼Melissa officinalis; SCI¼ spinal cord injury.
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This research was hinged on the promotion of the
therapeutic properties of hUCBSCs in combination
with a neuroprotective agent to induce curative eﬀects
to SCI in rats. The present study demonstrated that com-
bination of MO extract and hUCBSCs transplantation
has neuroprotective properties in treatment of SCI.
Although this combination promoted the motor, sensory,
and EMG functions, there were no signiﬁcant diﬀerences
between SCI-MO, SCI-hUCBSCs, and SCI-MO-
hUCBSC groups. A number of previous investigations
have revealed functional improvement after transplant-
ation of hUCBSCs in SCI (Saporta et al., 2003; Kuh
et al., 2005; Dasari, Spomar, et al., 2008; Rodrigues
et al., 2012). Previous research has shown that adminis-
tration of MO extract itself improved neurological and
cellular outcomes in rat SCI (Hosseini et al., 2015). MO
has neuroprotective and neurotrophic eﬀects, including
promotion of functional recovery, thereby suggesting
that it has therapeutic eﬀect on neurodegenerative dis-
eases (Bayat et al., 2012; Sepand et al., 2013). MO has
acetylcholinesterase inhibitory properties (Dastmalchi
et al., 2009). Anticholinesterases increase the residence
time of acetylcholine in the synapse. This allows rebind-
ing of the transmitter to nicotinic receptors. It thus gives
acetylcholine the competitive advantage over the neuro-
muscular blocking agent (Nair and Hunter, 2004). Our
results revealed that the combination of hUCBSCs and
MO prevented cell loss, formation of cavity, and astro-
gliosis in ventral horn and also enhances the myelination
in the dorsal white matter of spinal cord after injury. The
eﬀect of hUCBSCs and MO on enhancing functional
recovery, myelination, and reducing astrogliosis and
cavity formation is likely attributable to the inhibition
of pro-inﬂammatory cytokines. Inﬂammatory processes
have fundamental roles in the pathophysiology of SCI.
Figure 11. Effect of hUCBSC-MO treatment on density of
astrogliosis in ventral horn of spinal cord after injury.
Intraperitoneal injection of MO (150mg/kg) was started one day
after injury and continued once a day for 14 days after injury.
Intraspinal grafting of hUCBSCs was started 24 hr after injury. Data
are represented as mean of gliosis density SEM (n¼ 5–7) and
analyzed by one-way ANOVA followed by post hoc Bonferroni’s
multiple comparison test. ***p< .001 shows significant difference
between SCI versus intact. #p< .05, ##p< .01, and ###p< .001
versus spinal cord injury.  shows significant difference between
SCI-MO-hUCBSC and SCI-hUCBSC (p< .05). $$ shows significant
difference between SCI-MO-hUCBSC and SCI-MO (p< .05,
p< .01, and p< .001, respectively). Note. hUCBSCs¼ human
umbilical cord blood stem cells; MO¼Melissa officinalis;
SCI¼ spinal cord injury; SEM¼ standard error of the mean;
ANOVA¼ analysis of variance.
Figure 12. Effect of hUCBSC-MO treatment on density of myelin
in dorsal white matter of spinal cord after injury. Intraperitoneal
injection of MO (150mg/kg) was started one day after injury and
continued once a day for 14 days after injury. Intraspinal grafting of
hUCBSCs was started 24 hr after injury. Data are represented as
mean of myelin density SEM (n¼ 5–7) and analyzed by one-way
ANOVA followed by post hoc Bonferroni’s multiple comparison
test. ***p< .001 shows significant difference between SCI versus
intact. #p< .05 and ###p< .001 versus spinal cord injury.  shows
significant difference between SCI-MO-hUCBSC and SCI-hUCBSC
(p< .05). $$ shows significant difference between SCI-MO-
hUCBSC and SCI-MO (p< .05, p< .01, and p< .001, respectively).
Note. hUCBSCs¼ human umbilical cord blood stem cells;
MO¼Melissa officinalis; SCI¼ spinal cord injury; SEM¼ standard
error of the mean; ANOVA¼ analysis of variance.
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Pro-inﬂammatory cytokines, including IL-1 and TNF-a,
are released by activation of neurons, astrocytes,
microglia, and endothelial cells after injury. Thereafter,
the secondary inﬂammatory response and activation
of IL-6 and IL-8 are induced by those cytokines
(Zhu et al., 2014).
It has been shown that, transplantation of human
umbilical cord blood mesenchymal stem cells (hUCB-
MSCs) decreases the number of activated microglia and
inhibits the permeation of immune cells and cellular
apoptosis in the brain after ischemic brain injury (Yang
et al., 2013; Zhu et al., 2014; Wang et al., 2016).
Researchers have shown that the injection of hUCB-
MSCs throughout the early stage of ischemic brain
injury decreased the IL-1b, IL-6, and TNF-a expression
levels in the serum and increased IL-10 expression levels.
The signiﬁcant increase of pro-apoptotic genes such as
Bad, Bax, p53, AFAP1, caspase 3, and caspase 9 has
been observed after the SCI (Sabapathy et al., 2015).
IL-10 can decrease the expression of those genes,
oxygen free radicals, and cytokines. Upregulation of
IL-1b, IL-6, and TNF-a can initiate neuronal death and
improve the synthesis of nitric oxide after injury. IL-1b
can improve the intracellular calcium concentration and
release neurotropic factors, which can induce neuronal
apoptosis. Moreover, TNF-a can induce arachidonic
acid metabolite release, which enhance extracellular accu-
mulation of glutamate and generate neurodegenerative
toxicity. Glutamate-induced cell death in the CNS con-
tains upregulation of caspase 3 and its activation via
a caspase-dependent pathway involves mitochondrial sig-
naling. hUCBSCs decline caspase-3 and -7 activities
and are responsible for activation of the Akt pathway
and regulation of N-methyl-D-aspartic acid receptors,
thereby giving neuroprotection to cortical neurons
(Dasari, Veeravalli, et al., 2008). Therefore, hUCBSCs
Figure 13. Ultra structural characteristics of myelination in dorsal white matter of spinal cord at the level of T12-L1 of all groups which
were evaluated in this study on Day 56. (b) Low power view reveals the distribution of myelinated axons. Three representative high power
photographs show the typical appearance of myelinated axons with extensive myelin sheath wrapped around an axon (a, d, and e).
Densitometry of MBP in dorsal white matter of spinal cord at the level of T12-L1 is shown in the left part of any electron microscopy
pictures. a¼ Intact, b¼ SCI, c¼ SCI-MO, d¼ SCI-hUCBSC, e¼ SCI-MO-hUCBSC. Note. MBP¼myelin basic protein; hUCBSC¼ human
umbilical cord blood stem cell; MO¼Melissa officinalis; SCI¼ spinal cord injury.
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transplantation could provide neuroprotection by
regulating the balance of pro- and anti-inﬂammatory
cytokines.
Conversely, it has been shown that MO extracts
have anti-inﬂammatory properties (Bounihi et al., 2013;
Mu¨zell et al., 2013). Its anti-inﬂammatory eﬀects are due
to rosmarinic acid, ﬂavonoids, and terpenoids present in
the extract. Probably, ﬂavonoids have a more eﬀective
role by facilitating the synthesis of prostaglandin.
MO administration can suppress the pro-inﬂammatory
cytokines such as IL-1b, IL-6, and TNF-a (Bounihi
et al., 2013).
Our results have demonstrated that the combination of
MO extract administration and hUCBSCs transplant-
ation prevented cell loss and enhanced myelination.
A possible explanation to this is that, the transplantation
of hUCBSCs can increase the length of neuroﬁlament-
positive ﬁbers and increase the numbers of growth
cone-like structures at the lesion site. Grafted
hUCBSCs can survive, move over short distances, and
produce large amounts of glial cell line-derived neuro-
trophic factors and neurotrophin-3 (NT3) in the host
spinal cord (Rodrigues et al., 2012). It has also been con-
ﬁrmed that the hUCBSCs can form morphologically
myelin sheaths in the spinal cord. It has been revealed
that oligodendrocytes derived from human umbilical
cord blood secrete NT3 and brain-derived neurotrophic
factor. Cord blood stem cells promote the synthesis of
MBP and proteolipid protein in the injured areas, thereby
facilitating the process of remyelination (Dasari et al.,
2009). Conversely, a large number of experimental evi-
dences support oxidative stress as important mediators of
secondary cell death after SCI (Cuzzocrea and Genovese,
2008; Jia et al., 2012; Fatima et al., 2015). It has been
shown that administration of MO extract has powerful
antioxidant eﬀects which are probably exerted through
Figure 14. The effect of hUCBSC-MO treatment in reducing of
myelin index in dorsal white matter of the spinal cord after injury.
Intraperitoneal injection of MO (150mg/kg) was started one day
after injury and continued once a day for 14 days after injury.
Intraspinal grafting of hUCBSCs was started 24 hr after injury. Data
are represented as mean of myelin index SEM, (n¼ 2) and ana-
lyzed by one-way ANOVA followed by post-hoc Bonferroni’s mul-
tiple comparison test. ***p< .001 shows significant difference
between SCI versus intact. ##p< .01, and ###p< .001 versus
spinal cord injury.  shows significant difference between SCI-MO-
hUCBSC and SCI-hUCBSC (p< .05). $ shows significant difference
between SCI-MO-hUCBSC and SCI-MO (p< .05, p< .01, and
p< .001, respectively). Note. hUCBSCs¼ human umbilical cord
blood stem cells; MO¼Melissa officinalis; SCI¼ spinal cord injury;
SEM¼ standard error of the mean; ANOVA¼ analysis of variance.
Figure 15. The effect of hUCBSC-MO treatment in upregulation
of myelin basic protein in the spinal cord after injury. Intraperitoneal
injection of MO (150mg/kg) was started one day after injury and
continued once a day for 14 days after injury. Intraspinal grafting of
hUCBSCs was started 24 hr after injury. Data are represented as
mean of RT-PCR bands density SEM (n¼ 2) and analyzed by one-
way ANOVA followed by post hoc Bonferroni’s multiple compari-
son test. ***p< .001 shows significant difference between SCI
versus intact. #p< .05, ##p< .01, and ###p< .001 versus spinal
cord injury.  shows significant difference between SCI-MO-
hUCBSC and SCI-hUCBSC (p< .05). $, $$, and $$$ show signifi-
cant difference between SCI-MO-hUCBSC and SCI-MO (p< .05,
p< .01, and p< .001, respectively). Note. hUCBSCs¼ human
umbilical cord blood stem cells; MO¼Melissa officinalis;
SCI¼ spinal cord injury; SEM¼ standard error of the mean;
ANOVA¼ analysis of variance.
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the rosmarinic acid and the benzodioxole present in the
extract. Moreover, compounds such as linoleic acid, car-
nosic acid, and ursolic acid are also present in the
extracts, all of which have antioxidant properties.
The present study demonstrated that, the combination
of MO and hUCBSCs inhibited astrogliosis. This issue
has shown that the matrix metalloproteinase (MMP) as a
proteolytic enzyme advances functional recovery after
SCI by directing the development of a glial scar.
Treatment with hUCBSCs after SCI altered the expression
of diﬀerent MMPs in rats. hUCBSCs transplantation in
SCI causes upregulation of MMP-2 and therefore reduced
the development of the glial scar at the lesion site
(Veeravalli et al., 2009). In addition, as mentioned earlier,
MO extract can inhibit the pro-inﬂammatory cytokines and
reactive oxygen species. These two factors are key medi-
ators of reactive astrogliosis in SCI (Bharne et al., 2013).
The limitation of this study is the nonmeasurement of
the inﬂammatory factors and immunostaining for macro-
phage markers (F4/80 or Iba-1). Further investigations
on diﬀerentiation of hUCBSCs along with the use of
MO extracts will provide further evidence regarding the
therapeutic eﬀectiveness of hUCBSCs after SCI.
Conclusions
SCI causes motor and sensory dysfunction, tissue
deformity, and cell death, the formation of astrogliosis,
and degeneration of axons. In conclusion, hUCBSCs
enhanced motor and sensory dysfunction as well as pro-
moting morphological improvement in SCI contusion
model in comparison with SCI. Our results showed that
MO extract can promote the neuroprotective eﬀects of
hUCBSCs. Further studies are needed to clarify the
underlying mechanisms of these results.
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